CBIO CRESCENT BIOPHARMA, INC.

CIK 0001253689 11 ready 8-Ks latest Apr 29, 2026 23:59 UTC RSS · JSON

Ready 8-Ks 11

Latest filing Apr 29, 2026 23:59 UTC

Top materiality 1.00

Event mix earnings ×4 · m_and_a ×4 · other_material ×3

Sentiment 3 pos · 3 neg · 5 neu

Executive change recent →

Recent 8-K filings for CBIO

Highest-materiality recent filing

Crescent Biopharma completes reverse merger with GlycoMimetics; post-merger shares trade under CBIO

Jun 18, 2025 23:59 UTC m_and_a materiality 1.00 positive item 1.01 item 2.01 item 5.02 item 9.01 item 2.02 item 3.03 item 4.01 item 5.01 item 5.03 item 5.05 item 5.06 item 7.01

Former GlycoMimetics securityholders own ~2.7% of combined company; Crescent holders own ~97.3% on fully diluted basis.
Crescent raised ~$200M gross proceeds via pre-closing financing: 85.5M shares and 19.1M pre-funded warrants.

Read filing →

Apr 29, 2026 23:59 UTC earnings materiality 0.60 negative item 2.02 item 9.01

Crescent Biopharma Q1 net loss $23.3M; cash $189.2M funds ops into 2028

Net loss $23.3M ($0.70/sh) vs $15.1M ($19.63/sh) in Q1 2025; revenue $1.0M from Kelun-Biotech license.
Feb 26, 2026 23:59 UTC earnings materiality 0.70 negative item 2.02 item 9.01

Crescent Biopharma reports FY2025 net loss $153.9M, revenue $10.8M; cash $213.2M

Net loss of $92.4M ($4.01 per share) for Q4 2025 vs. $15.2M in prior year; FY net loss $153.9M.
Dec 04, 2025 23:59 UTC other_material materiality 0.85 positive item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Crescent Biopharma partners with Kelun-Biotech on CR-001/SKB105, raises $185M

Licenses CR-001 to Kelun-Biotech for Greater China; receives $20M upfront and up to $30M milestones.
Jul 31, 2025 23:59 UTC earnings materiality 0.85 positive item 2.02 item 5.02 item 9.01

Crescent Biopharma Q2 net loss $21.8M; merger & $200M financing closed

Net loss $21.8M ($4.93/share) for Q2 2025; R&D $12.1M, G&A $8.9M.
Jun 18, 2025 23:59 UTC m_and_a materiality 1.00 positive item 1.01 item 2.01 item 5.02 item 9.01 item 2.02 item 3.03 item 4.01 item 5.01 item 5.03 item 5.05 item 5.06 item 7.01

Crescent Biopharma completes reverse merger with GlycoMimetics; post-merger shares trade under CBIO

Former GlycoMimetics securityholders own ~2.7% of combined company; Crescent holders own ~97.3% on fully diluted basis.
Jun 06, 2025 23:59 UTC other_material materiality 0.70 neutral item 5.07 item 7.01 item 8.01 item 9.01

Stockholders approve merger with Crescent Biopharma; 1-for-100 reverse split

Stockholders approved all 10 proposals including merger agreement, stock issuance, charter amendments, reverse split, and equity plans.
May 30, 2025 23:59 UTC m_and_a materiality 0.70 neutral item 8.01

GlycoMimetics supplements merger disclosures; clarifies Crescent selection, $125M PIPE

GlycoMimetics chose Crescent over Party A (Chinese parent) due to regulatory clearance timing risks.
Apr 29, 2025 23:59 UTC m_and_a materiality 0.75 neutral item 1.01 item 9.01

GlycoMimetics amends Crescent merger; exchange ratio ~15.42 GLYC shares per Crescent share

Amendment clarifies Crescent RSUs will be assumed using the same exchange ratio as other Crescent securities.
Feb 25, 2025 23:59 UTC other_material materiality 0.85 negative item 1.02 item 5.02

GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart

Apollomics terminated the collaboration license for uproleselan and GMI-1687 in China, effective 90 days from Feb 19, 2025.
Feb 14, 2025 23:59 UTC m_and_a materiality 0.70 neutral item 1.01 item 9.01

GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities

Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.